AbCellera’s Coronavirus "Neutralizing" Antibody Leads Enter Screening
Summary
Now scientists at the National Institutes of Health, with which the company has been working to prepare medical countermeasures for pandemic outbreaks, are testing the candidates to determine which are most potent. It’s the latest step in an ambitious proposal by AbCellera and biopharma giant Eli Lilly (NYSE: LLY) to spin up an antibody product ready for human testing by the end of July that could potentially treat COVID-19, the respiratory illness caused by the deadly virus. ) AbCellera brings to the table its rapid screening platform developed by the company’s founding CEO, Carl Hansen, a professor at the University of British Columbia. The company developed software and custom machine learning tools to help with data visualization and other time-intensive tasks inherent in early drug discovery, she said. The company began preparing to put the platform to the test again, this time in service of impacting a real-time pandemic, once the first US COVID-19 patients were confirmed in early January.
Classifications
AskAI Classifications
LabelsLinked Companies
